http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#Head http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#assertion http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#provenance http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#pubinfo http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#assertion http://purl.obolibrary.org/obo/DOID_14330 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_14330 http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01200 http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#association http://www.w3.org/2000/01/rdf-schema#label bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia amenorrhea galactorrhea infertility or hypogonadism prolactin secreting adenomas reduction tumor size bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly bromocriptine mesylate tablets therapy alone or as adjunctive therapy with pituitary irradiation or surgery reduces serum growth hormone by 5 or more in approximately 1 2 of patients treated although not usually to normal levels since the effects of external pituitary radiation may not become maximal for several years adjunctive therapy with bromocriptine mesylate tablets offers potential benefit before the effects of irradiation are manifested bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic parkinson s disease as adjunctive treatment to levodopa alone or with a peripheral decarboxylase inhibitor bromocriptine mesylate tablets therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa those who are beginning to deteriorate develop tolerance to levodopa therapy and those who are experiencing end of dose failure on levodopa therapy bromocriptine mesylate tablets therapy may permit a reduction of the maintenance dose of levodopa and thus may ameliorate the occurrence and or severity of adverse reactions associated with long term levodopa therapy such as abnormal involuntary movements e g dyskinesias and the marked swings in motor function on off phenomenon continued efficacy of bromocriptine mesylate tablets therapy during treatment of more than 2 years has not been established data are insufficient to evaluate potential benefit from treating newly diagnosed parkinson s disease with bromocriptine mesylate tablets studies have shown however significantly more adverse reactions notably nausea hallucinations confusion and hypotension in bromocriptine mesylate treated patients than in levodopa carbidopa treated patients patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets therapy http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB01200 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#provenance http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#pubinfo http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#sig http://purl.org/nanopub/x/hasSignature WuC7SmL/eE6iuoTC2f/WUKTCvm6YbmvMphI7d8opwoen+EuXwOneE6Af4jLF5KQxXH5i4B35eyYeBoE4ZFpFPllVar/1igifLNBdfLaa17pcYJjRoYCWnCUaqrhRk4SgbxGlehvlBtJbjvEg4+5FSK2HkoOne1gmqOf8qL+49Wo= http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI http://purl.org/dc/terms/created 2021-07-03T12:03:24.167+02:00 http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAwx1MvQXRQB51W_J6AYs6X_QrYKdBv4E3EXXYRjaVJMI https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs